-
Ƶ Announces New Leadership to Drive Commercialization of INDUCE-seq® Platform for Gene Editing On- and Off-target Characterization
CAMBRIDGE, UK – November 17th, 2025 – Ƶ (“Broken String”), a leader in advancing gene editing safety, today announced the appointment of new leadership to drive the commercialization of its INDUCE-seq® platform, now available to cell and gene therapy developers worldwide. To drive the company’s commercial expansion, Terry Pizzie has been appointed as…
-
Ƶ and the Francis Crick Institute collaborate to advance ALS research
Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis Cambridge, UK, 7 May 2024: Ƶ (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has entered a research collaboration with…
-
Ƶ’ INDUCE-seq platform demonstrates impact of structural DNA changes on specificity of CRISPR-Cas9 gene editing
Cambridge, UK, 18 October 2023: Ƶ (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that its INDUCE-seq™ DNA break-mapping technology had been used in a peer-reviewed research paper to characterize off-target effects of CRISPR-Cas9 gene editing…
-
Ƶ Closes $15M Series A Funding Round
Cambridge, UK, 18 September 2023: Ƶ (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from…
